机构：[1]State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.四川大学华西医院[2]Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China.[3]Department of Immunology, Nankai University School of Medicine, Nankai, Tianjin 300071, P.R. China.
Vaccines are critical tools for the prevention and treatment of several diseases. Adjuvants have been traditionally used to enhance immunity to vaccines and experimental antigens. In the present study, the adjuvant combination of CpG oligodeoxynucleotides (CpG ODN) and the innate defense regulator (IDR) peptide, IDR‑HH2, was evaluated for its ability to enhance and modulate the immune response when formulated with alum and the recombinant hepatitis B surface antigen (HBsAg). The CpG‑HH2 complex enhanced the secretions of tumor necrosis factor‑α, monocyte chemotactic protein 1 and interferon‑γ by human peripheral blood mononuclear cells and promoted murine bone marrow dentritic cell maturation. In addition, the present study demonstrated that IDR‑HH2 was chemotactic for human neutrophils, THP‑1 cells and RAW264.7 cells at concentrations between 2.5 and 40 µg/ml. The present study also observed that significantly higher anti‑HBs antibody titers, which were sustained at high levels for as long as 35 weeks following the boost immunization, were induced by the combination adjuvant, even when co‑administered with a commercial hepatitis B vaccine at a low antigen dose (0.1 µg HBsAg). Notably, the level of IgG2a was almost equal to the level of IgG1, indicating that a balanced T helper (Th)1/Th2 immune response was elicited by the novel vaccine, which was consistent with the ELISpot results. These data suggest that the CpG‑HH2 complex may be a potential effective adjuvant, which facilitates a reduction in the dose of antigen and induces long‑lasting, balanced immune responses.
基金：
The study was supported by the National Major Scientific
and Technological Special Project for ‘Significant New
Drugs Development’ (grant. no. 2013ZX09102030) and the
Foundation for Sichuan Distinguished Young Academic and
Technology Leaders (grant. no. 2012JQ0014)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|4 区医学：研究与实验4 区肿瘤学
第一作者：
第一作者机构：[1]State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
共同第一作者：
通讯作者：
通讯机构：[1]State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.[*1]State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, 4 Keyuan Road, Gaopeng Street, Chengdu, Sichuan 610041, P.R. China
推荐引用方式(GB/T 7714)：
Yu Chao-Heng,Luo Zi-Chao,Li Meng,et al.Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses.[J].Molecular medicine reports.2016,13(1):915-24.doi:10.3892/mmr.2015.4581.
APA：
Yu Chao-Heng,Luo Zi-Chao,Li Meng,Lu Lian,Li Zhan...&Yang Li.(2016).Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses..Molecular medicine reports,13,(1)
MLA：
Yu Chao-Heng,et al."Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses.".Molecular medicine reports 13..1(2016):915-24
